A class action lawsuit has been filed against Replimune Group, Inc. alleging the company failed to disclose critical issues related to its FDA Biologics License Application (BLA). The lawsuit claims Replimune did not address FDA concerns about study design and submitted incomplete data from a small patient group, likely leading to FDA rejection of the BLA. Investors argue that the company's positive statements about its business and prospects were misleading. The case is pending in the U.S. District Court for the District of Massachusetts, with a lead plaintiff motion deadline on October 5, 2026.
BMO Capital initiated coverage on Tenet Healthcare with a 'Market Perform' rating, indicating the stock is expected to perform in line with the broader market. The company is forecasted to report a 24.05% increase in Earnings Per Share (EPS) to $4.59...
Jaguar Health (JAGX) surged over 1,150% after the FDA granted fee waivers for its drugs Mytesi and Canalevia-CA1, signaling regulatory support. Greenland Mines (GRML) rose nearly 50% amid growing investor interest linked to U.S.-Greenland security de...
The market experienced a downturn with significant losses among key stocks. New Fortress Energy dropped 24.7% amid ongoing volatility in energy sectors, while Xanadu Quantum Technologies fell 21.7% reflecting sensitivity in quantum stocks to commerci...
Jefferies maintains a Hold rating on Capri Holdings due to uncertainty over a potential takeover. Despite a flat global luxury market, Capri's management expects growth in the second half of 2026, driven by new product launches, increased marketing, ...
The VanEck Agribusiness ETF (MOO) has gained about 20% since the last review, driven by geopolitical disruptions and government support for agriculture. However, the ETF is downgraded to a hold as these positive factors seem priced in, and margin pre...
